When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
BMY - bluebird bio's Current Price Levels Offer An Attractive Risk-Return Play
Bristol-Myers Squibb Company
bluebird bio's new therapies have strict labels due to health concerns over severe side effects, limiting the addressable markets of these new therapies.
Toxicities of bluebird's new therapies point to shortcomings of its CAR-T and Leniglobin technology, lowering the economic moat of its patent portfolio.
The company is trading at a record low, reflecting the risks that emerged in recent quarters, but don't incorporate the possible success of Abecma for multiple myeloma.